The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2021 | Elotuzumab, pomalidomide, and dexamethasone for advanced myeloma
Stefan Knop, MD, University Hospital of Würzburg, Würzburg, Germany, shares the findings of a retrospective study investigating the treatment of patients with multiple myeloma using elotuzumab, pomalidomide and dexamethasone. In this trial, 22 patients with advanced multiple myeloma were treated with this triplet combination. The study reported a median progression-free survival (PFS) of over seven months, with no difference between patients with standard- or high-risk disease, as defined by cytogenetics. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.
